Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Dosage adjustments of biological and related drugs for lung cancer
- At: 2018 FIP Congress in Glasgow (Scotland)
- Type: Poster
- By: MORGADO, Manuel (University of Beira Interior, Health Science Faculty)
- Co-author(s): Cláudia Loureiro: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
Diana Lopes: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
Ema Paulino: Portuguese Pharmaceutical Society, Lisbon, Portugal
Manuel Morgado: Health Science Faculty, University of Beira Interior, Covilhã, Portugal;Higher School of Health, Polytechnic Institute of Guarda, Guarda, Portugal;Pharmaceutical Services, Hospital Centre of Cova da Beira, Covilhã, Portugal
BackgroundLung cancer is cancer with highest mortality rate in Portugal. In the last years, the pharmaceutical industry has developed new biological drugs for this type of cancer. It is important to understand which dosage adjustments are required in patients with comorbid renal or hepatic impairment for effective and safe therapy.
The human.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019